home / stock / bctx / bctx news

BCTX News and Press, BriaCell Therapeutics Corp. From 05/15/24

Stock Information
Company Name: BriaCell Therapeutics Corp.
Stock Symbol: BCTX
Market: NASDAQ
Website: briacell.com
Menu
BCTX BCTX Quote BCTX Short BCTX News BCTX Articles BCTX Message Board
Get BCTX Alerts

News, Short Squeeze, Breakout and More Instantly...
BCTX - BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...
BCTX - BriaCell Announces Oral and Poster Presentations at ASCO 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD Two poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columb...

BCTX - BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cells The novel mechanisms of actio...

BCTX - BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bri...
BCTX - BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024

2024-03-19 06:52:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BriaCell Therapeutics (NASDAQ: BCTX ) just reported results for the second quarter of 2024. BriaCell Therapeutics reported earnings per share of -71 cents. The company...

BCTX - BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British...

BCTX - BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer c...
BCTX - BriaCell Provides Update on Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology  company that develops novel immunotherapies t...

BCTX - BriaCell shares rise on strong data from breast cancer treatment study

2024-02-07 08:30:54 ET More on Briacell Therapeutics, BriaCell Therapeutics Corp. WT EX 022425, etc. Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics ...

BCTX - BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy...
Previous 10 Next 10